Cross-Kingdom Small RNAs among Animals, Plants and Microbes

Zeng, Jun; Gupta, Vijai Kumar; Jiang, Yueming; Yang, Bao; Gong, Liang; Zhu, Hong

doi:10.3390/cells8040371

Cited by 86 publications

(67 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 In contrast to the microRNAs and siRNAs, antisense RNAs are single-stranded RNAs which are naturally occurring or synthetic and usually around 19−23 nucleotides in length with a sequence complementary to that of a protein coding mRNA, allowing it to hybridize and block protein translation. 48 Since the discovery of RNAi in the late 1990s, it has become a well-known method for silencing/suppressing target genes associated with virulence and pathogenesis. Thirty-five patents in the CAS content collection disclose the use of RNAi in treating SARS, with 28 patents using siRNA molecules, three patents using antisense oligonucleotides, two patents using RNA aptamers, one patent using a ribozyme, and one patent using a microRNA inhibitor.…”

Section: Diseasesmentioning

confidence: 99%

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

et al. 2020

View full text Add to dashboard Cite

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection. It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication. The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV. The patent analysis of coronavirus-related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines. More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19. The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.

show abstract

Section: Diseasesmentioning

confidence: 99%

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Noncoding RNAs refer to a class of RNA molecules that cannot be translated into proteins . They are mainly classified into short‐chain (including siRNA, miRNA, piRNA) and long‐length (long noncoding RNA, lncRNA) according to their length . LncRNA is a type of RNA which is longer than 200 in length and does not have the function of encoding protein .…”

Section: Introductionmentioning

confidence: 99%

LncRNA GMDS‐AS1 inhibits lung adenocarcinoma development by regulating miR‐96‐5p/CYLD signaling

Zhao

Zhang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

According to the global cancer statistic, lung cancer is one of the most dangerous tumors, which poses a serious threat to human health. Exploration the mechanism of lung cancer and new targeted therapeutic measures is always the hot topic. Long noncoding RNA (lncRNA) is an important factor affecting the development of tumors. However, the research on the mechanism of lncRNA in the progress of lung cancer needs to be further expanded. In this study, we found that the expression of lncRNA GMDS‐AS1 was significantly reduced in lung adenocarcinoma (LUAD) tissues and cells. Upregulated GMDS‐AS1 can significantly inhibit the proliferation of LUAD cells and promote cell apoptosis in vitro and in vivo. The results indicate that GMDS‐AS1 acts as a tumor suppressor gene to affect the development of LUAD. Further studies revealed that GMDS‐AS1 is a target gene of miR‐96‐5p, and GMDS‐AS1 regulates proliferation and apoptosis of LUAD cells in association with miR‐96‐5p. In addition, we also confirmed that CYLD lysine 63 deubiquitinase (CYLD) is also a target gene of miR‐96‐5p. Through various validations, we confirmed that GMDS‐AS1 can act as a ceRNA to upregulate the expression of CYLD by sponging miR‐96‐5p. Moreover, the intervention of GMDS‐AS1/miR‐96‐5p/CYLD network can regulate the proliferation and apoptosis of LUAD cells. In this study, we revealed that the GMDS‐AS1/miR‐96‐5p/CYLD network based on ceRNA mechanism plays an important role in the development of LUAD and provides a new direction and theoretical basis for targeted therapy of LUAD.

show abstract

“…This biotechnological method, called host-induced gene silencing (HIGS), has emerged as a promising alternative to other plant protection methods, because it is highly selective relative to the target organism's genes. In addition, this method has minimal side effects compared, e.g., with protein-producing transgenes or chemical protective treatment [29,33].…”

Section: Plant Genomic Dna Plantmentioning

confidence: 99%

“…Over the past 10 years, a number of studies on the use of HIGS to combat fungal diseases have been published [29,33,34]. The efficiency of HIGS in fighting against phytopathogenic fungi was proved in an important study published in 2010 [35].…”

Section: Plant Genomic Dna Plantmentioning

confidence: 99%

Double-Stranded RNAs in Plant Protection Against Pathogenic Organisms and Viruses in Agriculture

et al. 2019

View full text Add to dashboard Cite

Recent studies have shown that plants are able to express the artificial genes responsible for the synthesis of double-stranded RNAs (dsRNAs) and hairpin double-stranded RNAs (hpRNAs), as well as uptake and process exogenous dsRNAs and hpRNAs to suppress the gene expression of plant pathogenic viruses, fungi, or insects. Both endogenous and exogenous dsRNAs are processed into small interfering RNAs (siRNAs) that can spread locally and systemically through the plant, enter pathogenic microorganisms, and induce RNA interference-mediated pathogen resistance in plants. There are numerous examples of the development of new biotechnological approaches to plant protection using transgenic plants and exogenous dsRNAs. This review summarizes new data on the use of transgenes and exogenous dsRNAs for the suppression of fungal and insect virulence genes, as well as viruses to increase the resistance of plants to these pathogens. We also analyzed the current ideas about the mechanisms of dsRNA processing and transport in plants.

show abstract

Cross-Kingdom Small RNAs among Animals, Plants and Microbes

Cited by 86 publications

References 108 publications

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

LncRNA GMDS‐AS1 inhibits lung adenocarcinoma development by regulating miR‐96‐5p/CYLD signaling

Double-Stranded RNAs in Plant Protection Against Pathogenic Organisms and Viruses in Agriculture

Contact Info

Product

Resources

About